Overview
Compare with PROCEPT BioRobotics Corp, ANGIODYNAMICS INC or TACTILE SYSTEMS TECHNOLOGY INC, or pick any stock.
- TickerSKIN on Nasdaq2
- IndustrySurgical & Medical Instruments & Apparatus2
- HeadquartersLong Beach, United States2
- Incorporated inDE3
- Business address3600 E. Burnett Street, Long Beach, Ca 908153
- Filer categoryAccelerated filer3
- Legal formCorporation2
- LEI5493001Z2JZQT4C63C502
- StatusActive2
- LEI statusIssued and current2
- Registered addressc/o CORPORATION SERVICE COMPANY, 251 LITTLE FALLS DRIVE, 19808 Wilmington, United States2
- Registered withDivision of Corporations, Department of State, 32100322
See how the biggest companies compare on our leaderboards
The Beauty Health Company (the “Company” or “we”) is a global medical aesthetics company delivering an integrated ecosystem of clinically proven solutions designed to help consumers achieve superior skin health and support the success of providers. Anchored by Hydrafacial, a leading and widely requested professional skincare treatment, and supported by complementary offerings including SkinStylus microneedling and HydraScalp powered by Keravive, the Company combines advanced device technology, proprietary consumables, and clinical validation to deliver trusted treatment experiences through an omnichannel network of providers worldwide.5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue35¢$104.4M
- Research and development2¢$5.6M
- Other costs62¢$187.2M
- Income tax1¢$3.6M
Out of $300.8M in revenue.6 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Capital spending1¢$303.0K
- Kept or used elsewhere99¢$37.2M
Out of $37.5M of cash from operations.6
Financial statements
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $166.6M7 | $119.1M8 | $260.1M9 | $365.9M10 | $398.0M6 | $334.3M6 | $300.8M6 |
| Cost of revenue | $60.1M7 | $51.9M8 | $81.5M9 | $117.1M10 | $242.9M6 | $152.0M6 | $104.4M6 |
| Gross profit | $106.5M7 | $67.2M8 | $178.5M9 | $248.8M10 | $155.1M6 | $182.3M6 | $196.4M6 |
| Research and development | $4.6M7 | $3.4M8 | $8.2M9 | $8.4M10 | $10.1M6 | $6.3M6 | $5.6M6 |
| Operating expenses | $218.5M9 | $274.6M10 | $286.0M6 | $250.1M6 | $217.2M6 | ||
| Operating income | $13.5M7 | -$17.2M8 | -$39.9M9 | -$25.8M10 | -$130.9M6 | -$67.8M6 | -$20.8M6 |
| Interest | $11.8M9 | $13.4M9 | $13.6M9 | ||||
| Income before tax | -$380.6M9 | $45.3M10 | -$101.9M6 | -$29.6M6 | -$5.9M6 | ||
| Income tax | -$1.3M7 | -$9.3M8 | -$1.9M9 | $1.1M10 | -$1.8M6 | -$452.0K6 | $3.6M6 |
| Net income | -$1.6M7 | -$29.2M8 | -$378.8M9 | $44.2M10 | -$100.1M6 | -$29.1M6 | -$9.5M6 |
| Earnings per share | -$0.057 | -$0.858 | -$3.719 | $0.3010 | -$0.766 | -$0.236 | -$0.086 |
| Earnings per share (diluted) | -$0.057 | -$0.858 | -$3.719 | -$0.2310 | -$0.766 | -$0.366 | -$0.166 |
| Shares (weighted, basic) | 102.1M shares9 | 147.6M shares10 | 131.7M shares6 | 123.8M shares6 | 126.4M shares6 | ||
| Shares (weighted, diluted) | 102.1M shares9 | 148.5M shares10 | 131.7M shares6 | 142.5M shares6 | 135.8M shares6 |
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash | $7.3M8 | $9.5M7 | $901.9M8 | $568.2M9 | $523.0M9 | $370.1M6 | $232.7M6 |
| Receivables | $46.8M8 | $76.5M9 | $54.7M10 | $27.6M6 | $21.7M6 | ||
| Inventory | $35.3M8 | $109.7M9 | $91.3M10 | $69.1M6 | $48.0M6 | ||
| Current assets | $59.1M7 | $1.0B8 | $783.3M9 | $698.3M10 | $477.1M6 | $309.5M6 | |
| Goodwill | $123.7M9 | $124.6M9 | $125.8M6 | $123.5M6 | $126.6M6 | ||
| Intangible assets | $56.0M8 | $46.4M9 | $62.1M10 | $47.5M6 | $35.8M6 | ||
| Total assets | $222.8M7 | $1.2B8 | $1.0B9 | $929.1M10 | $685.7M6 | $499.8M6 | |
| Accounts payable | $29.0M8 | $28.5M9 | $44.8M10 | $21.9M6 | $15.6M6 | ||
| Current liabilities | $30.9M7 | $76.4M8 | $71.7M9 | $115.0M10 | $68.2M6 | $186.3M6 | |
| Total liabilities | $252.8M7 | $916.5M8 | $836.0M9 | $869.7M10 | $633.9M6 | $438.7M6 | |
| Retained earnings | -$418.7M8 | -$378.8M9 | -$478.9M10 | -$508.0M6 | -$517.5M6 | ||
| Shareholders’ equity | -$1.2M8 | -$30.6M9 | $298.0M10 | $167.1M6 | $59.4M6 | $51.8M6 | $61.1M6 |
| Shares outstanding | 32.1M shares7 | 35.5M shares7 | 150.6M shares8 | 132.2M shares9 | 122.9M shares10 | 124.9M shares6 | 127.5M shares6 |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operations | $1.7M7 | -$12.4M8 | -$28.4M9 | -$106.6M10 | $21.8M6 | $16.1M6 | $37.5M6 |
| Stock-based compensation | $12.4M9 | $28.5M10 | $22.5M6 | $26.7M6 | $14.8M6 | ||
| Capital spending | $8.8M7 | $3.5M8 | $11.2M9 | $10.8M10 | $3.8M6 | $756.0K6 | $303.0K6 |
| Free cash flow | -$7.0M | -$15.9M | -$39.6M | -$117.4M | $17.9M | $15.4M | $37.2M |
| Cash from investing | -$37.7M9 | -$18.9M10 | -$31.5M6 | -$6.8M6 | -$5.2M6 | ||
| Share buybacks | $07 | $154.0K8 | $09 | $160.0M10 | $30.2M6 | $06 | $06 |
| Cash from financing | $959.0M9 | -$205.2M10 | -$37.4M6 | -$158.3M6 | -$174.9M6 |
Corporate structure
SkinHealth Systems Inc. sits at the top of its group. 15 entities, 9 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of SkinHealth Systems Inc.
- BlackRock Filed SCHEDULE 13G/A on SkinHealth Systems Inc., latest Jul 27, 2026 (2 filings since Jul 17, 2025)
- BlackRock Portfolio Management LLC Filed SCHEDULE 13G on SkinHealth Systems Inc., latest Jul 17, 2026
- Capricorn Fund Managers Ltd Filed SCHEDULE 13G/A on SkinHealth Systems Inc., latest Jul 13, 2026 (2 filings since Feb 5, 2026)
- FMR LLC Filed SCHEDULE 13G/A on SkinHealth Systems Inc., latest Jul 8, 2026 (7 filings since Feb 9, 2022)
- Brian Christopher Miller Filed SCHEDULE 13D/A on SkinHealth Systems Inc., latest May 11, 2026
- INTEGRATED CORE STRATEGIES (US) LLC Filed SCHEDULE 13G on SkinHealth Systems Inc., latest Apr 20, 2026
- MIRABELLA FINANCIAL SERVICES LLP Filed SCHEDULE 13G/A on SkinHealth Systems Inc., latest Feb 6, 2026 (3 filings since Jan 31, 2025)
- Janus Henderson Group Ltd. Filed SCHEDULE 13G/A on SkinHealth Systems Inc., latest Aug 14, 2025 (8 filings since Feb 13, 2023)
- Divisadero Street Capital Management, LP Filed SC 13G/A on SkinHealth Systems Inc., latest Nov 14, 2024 (2 filings since May 17, 2024)
- Luxor Capital Partners, LP Filed SC 13G/A on SkinHealth Systems Inc., latest Nov 14, 2024
- VANGUARD GROUP INC Filed SC 13G/A on SkinHealth Systems Inc., latest Nov 12, 2024 (5 filings since Feb 9, 2022)
- LCP Edge Holdco LLC Filed SC 13D/A on SkinHealth Systems Inc., latest Mar 14, 2024 (2 filings since Jul 7, 2023)
- SkinHealth Systems Inc. Long Beach, California, United States
- Edge Systems Holdings Corporation Subsidiary · Delaware, United States
- Edge Systems Intermediate, LLC Subsidiary · Delaware, United States
- Esthetic Medical Inc. Subsidiary · California, United States
- HydraFacial Australia and New Zealand Pty Ltd. Subsidiary · Australia
- Hydrafacial Canada Esthetic Products Inc. Subsidiary · Canada
- HydraFacial France Subsidiary · France
- HydraFacial Germany GmbH Subsidiary · Germany
- HydraFacial LLC Subsidiary · California, United States
- HydraFacial Trading (Shanghai) Co., Ltd. Subsidiary · China
- HydraFacial UK Limited Subsidiary · United Kingdom
- LCP Edge Intermediate, LLC Subsidiary · Delaware, United States
- The HydraFacial Company Iberia, S.L.U Subsidiary · Spain
- The HydraFacial Company Mexico Holdings, LLC Subsidiary · Delaware, United States
- The HydraFacial Company MX, S. de R.L. de C.V. Subsidiary · Mexico
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What SkinHealth Systems Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Operating-lease assets (leased space) | $11.6M6 Dec 31, 2025 | $13.6M6 Dec 31, 2024 | −14.9% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $126.6M6 Dec 31, 2025 | $123.5M6 Dec 31, 2024 | +2.5% |
| Finite-lived intangibles, gross | $159.5M6 Dec 31, 2025 | $153.4M6 Dec 31, 2024 | +3.9% |
| Accumulated amortization | $123.7M6 Dec 31, 2025 | $105.9M6 Dec 31, 2024 | +16.8% |
| Finite-lived intangibles, net | $35.8M6 Dec 31, 2025 | $47.5M6 Dec 31, 2024 | −24.7% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $48.0M6 Dec 31, 2025 | $69.1M6 Dec 31, 2024 | −30.5% |
| Raw materials | $18.5M6 Dec 31, 2025 | $26.0M6 Dec 31, 2024 | −28.7% |
| Finished goods | $29.5M6 Dec 31, 2025 | $43.1M6 Dec 31, 2024 | −31.6% |
Properties, in its own words
Our principal executive office is located in Long Beach, California, where we lease a warehouse that is approximately 105,000 square feet, that serves as our headquarters, distribution center, manufacturing facility, and production facility. We also lease approximately 23,000 square feet of additional office space in Long Beach, California, of which approximately 15,000 square feet is sublet to a sublessee.
We occupy an experience center in New York, and outside of the United States, we lease office and/or warehouse space in Australia, Spain, France, Germany, the United Kingdom, and Mexico for employees in those markets.
The rest of Item 2
We believe our present facilities are suitable and adequate for our current operating needs. We do not own any real property.
Item 2 of the 10-K filed Mar 12, 2026.5
Leadership
Who has led SkinHealth Systems Inc., and when. Pick a name to see everywhere that person has worked.
President
Chief financial officer
Chief operating officer
- Chief executive officerPedro Bruno Ferreira Malha Oct 10, 2025 to now13
- Chief executive officerAndrew Roy Stanleick Feb 9, 2022 to Aug 17, 202314
- Chief executive officerBrent Saunders Sep 29, 2020 to Sep 29, 202015
- ChairBrent Saunders Sep 29, 2020 to May 10, 202115
- PresidentPedro Bruno Ferreira Malha Oct 10, 2025 to now13
- PresidentIndra Pamamull Aug 13, 2021 to Feb 8, 202216
- PresidentStephan Becker Oct 5, 2021 to Feb 8, 202217
- PresidentBrent Saunders Sep 29, 2020 to Sep 29, 202015
- Chief financial officerLiyuan Woo May 10, 2021 to Apr 6, 202318
- Chief financial officerManisha Narasimhan Sep 29, 2020 to Sep 29, 202019
- Chief operating officerSheri Lewis Feb 28, 2025 to now20
- Chief operating officerBradley Hauser Apr 19, 2023 to Dec 1, 202321
Board members and other officers (17)
- Chief Revenue OfficerRonald Menezes Feb 28, 2025 to now22
- OfficerDaniel Copell Watson May 10, 2021 to Jun 11, 202423
- Board memberE. Scott Beattie Apr 22, 2026 to now24
- Board memberKenneth Robert Tripp Apr 22, 2026 to now25
- Board memberSachin Mahavir Shridharani Apr 22, 2026 to now26
- Board memberPedro Bruno Ferreira Malha Oct 10, 2025 to now13
- Board memberPhilippe Schaison Nov 3, 2025 to now27
- Board memberStephen J. Fanning Dec 30, 2024 to now28
- Board memberAndrew Roy Stanleick Feb 9, 2022 to Aug 17, 202314
- Board memberBrian Christopher Miller May 10, 2021 to now29
- Board memberDoug K. Schillinger May 10, 2021 to now30
- Board memberMichelle C. Kerrick May 10, 2021 to now31
- Board memberBrent Saunders May 18, 2021 to now32
- Board memberDesiree Gruber Jun 21, 2021 to now33
- Board memberJulius Few Sep 29, 2020 to Jul 10, 202434
- Board memberManisha Narasimhan Sep 29, 2020 to Sep 29, 202019
- Board memberMichael David Capellas Sep 29, 2020 to Jul 10, 202435
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- Edge Systems Holdings Corporation Delaware4
- Edge Systems Intermediate, LLC Delaware4
- Esthetic Medical Inc. California4
- HydraFacial Australia and New Zealand Pty Ltd. Australia4
- HydraFacial France France4
- HydraFacial Germany GmbH Germany4
- HydraFacial LLC California4
- HydraFacial Trading (Shanghai) Co., Ltd. China4
- HydraFacial UK Limited United Kingdom4
- Hydrafacial Canada Esthetic Products Inc. Canada4
- LCP Edge Intermediate, LLC Delaware4
- The HydraFacial Company Iberia, S.L.U Spain4
- The HydraFacial Company MX, S. de R.L. de C.V. Mexico4
- The HydraFacial Company Mexico Holdings, LLC Delaware4
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
Timeline
- Oct 14, 20268-K Change to shareholders' rights; Bylaws or fiscal year changed; Regulation FD disclosure36
- Oct 6, 20268-K Ended a material agreement; Regulation FD disclosure37
- Sep 28, 20268-K Shareholder vote38
- Sep 10, 20268-K Executive or director change39
- Aug 14, 20268-K Executive or director change40
- Aug 6, 20268-K Results of operations41
- Jun 22, 20268-K Other events42
- Jun 16, 20268-K Shareholder vote43
- May 21, 20268-K Executive or director change44
- May 12, 20268-K Listing notice or transfer45
- May 7, 20268-K Results of operations46
- May 6, 20268-K Executive or director change47
- Oct 10, 2025New chief executive Pedro Bruno Ferreira Malha becomes CEO13
- Feb 9, 2022New chief executive Andrew Roy Stanleick becomes CEO14
- Sep 29, 2020New chief executive Brent Saunders becomes CEO15
- Jul 8, 2020Founded SkinHealth Systems Inc. is founded2
Calendar
Coming up
- Nov 5, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($1.80) a share, on Nov 6, 2025.48
When it reported results
- Aug 6, 2026Reported quarterly or annual results41
- May 7, 2026Reported quarterly or annual results46
- Mar 12, 2026Reported quarterly or annual results49
- Nov 6, 2025Reported quarterly or annual results50
- Aug 7, 2025Reported quarterly or annual results51
- May 8, 2025Reported quarterly or annual results52
- Mar 12, 2025Reported quarterly or annual results53
- Nov 12, 2024Reported quarterly or annual results54
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
317 filings to the SEC since October 2021: 6 annual reports, 18 quarterly reports, 82 major events, 108 insider forms, 42 large holders, 61 other. The latest 20:
- Oct 14, 20268-K EDGAR
- Oct 13, 20264 EDGAR
- Oct 6, 20268-K EDGAR
- Sep 28, 20268-K EDGAR
- Sep 10, 20268-K EDGAR
- Aug 14, 20268-K EDGAR
- Aug 12, 2026DEFA14A ADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALS EDGAR
- Aug 12, 2026DEF 14A DEFINITIVE PROXY STATEMENT EDGAR
- Aug 12, 20264 EDGAR
- Aug 6, 202610-Q EDGAR
- Aug 6, 20268-K EDGAR
- Jul 31, 2026PRE 14A PRELIMINARY PROXY STATEMENT EDGAR
- Jul 27, 2026SCHEDULE 13G/A EDGAR
- Jul 17, 2026SCHEDULE 13G EDGAR
- Jul 13, 2026SCHEDULE 13G/A EDGAR
- Jul 8, 2026SCHEDULE 13G/A EDGAR
- Jun 22, 20268-K EDGAR
- Jun 16, 20268-K EDGAR
- May 21, 20268-K/A EDGAR
- May 20, 2026144 EDGAR
The 317 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
9 open-market trades by officers, directors and large owners since October 2021: 8 buys and 1 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 20, 2024 | Gruber DesireeDirector | Sale | 14,663 | $1.50 | $22.0K | Form 4 |
| Aug 12, 2024 | SAUNDERS BRENT LDirector | Buy | 40,450 | $1.08 | $43.7K | Form 4 |
| Aug 17, 2023 | Miller Brian ChristopherDirector | Buy | 60,000 | $5.81 | $348.6K | Form 4 |
| Aug 17, 2023 | CAPELLAS MICHAEL DDirector | Buy | 30,000 | $6.03 | $180.9K | Form 4 |
| Aug 17, 2023 | MONAHAN MICHAEL P.Chief Financial Officer | Buy | 5,000 | $6.02 | $30.1K | Form 4 |
| Aug 17, 2023 | Stanleick Andrew RoyChief Executive Officer | Buy | 16,485 | $6.05 | $99.7K | Form 4 |
| Aug 16, 2023 | Few JuliusDirector | Buy | 20,454 | $6.10 | $124.8K | Form 4 |
| Aug 16, 2023 | Schillinger Doug K.Director | Buy | 33,000 | $6.11 | $201.6K | Form 4 |
| Aug 16, 2023 | SAUNDERS BRENT LDirector | Buy | 59,380 | $6.10 | $362.2K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- BlackRockSCHEDULE 13G/A, 2 filings Jul 17, 2025 to Jul 27, 202655
- BlackRock Portfolio Management LLCSCHEDULE 13G, 1 filing Jul 17, 202656
- Capricorn Fund Managers LtdSCHEDULE 13G/A, 2 filings Feb 5, 2026 to Jul 13, 202657
- FMR LLCSCHEDULE 13G/A, 7 filings Feb 9, 2022 to Jul 8, 202658
- Brian Christopher MillerSCHEDULE 13D/A, 1 filing May 11, 202659
- INTEGRATED CORE STRATEGIES (US) LLCSCHEDULE 13G, 1 filing Apr 20, 202660
- MIRABELLA FINANCIAL SERVICES LLPSCHEDULE 13G/A, 3 filings Jan 31, 2025 to Feb 6, 202661
- Janus Henderson Group Ltd.SCHEDULE 13G/A, 8 filings Feb 13, 2023 to Aug 14, 202562
- Divisadero Street Capital Management, LPSC 13G/A, 2 filings May 17, 2024 to Nov 14, 202463
- Luxor Capital Partners, LPSC 13G/A, 1 filing Nov 14, 202464
- VANGUARD GROUP INCSC 13G/A, 5 filings Feb 9, 2022 to Nov 12, 202465
- LCP Edge Holdco LLCSC 13D/A, 2 filings Jul 7, 2023 to Mar 14, 202466
- Luxor Capital Group, LPSC 13G/A, 4 filings Feb 14, 2022 to Feb 14, 202467
- Senvest Management, LLCSC 13G/A, 2 filings Jun 2, 2023 to Feb 9, 202468
- BAUPOST GROUP LLC/MASC 13G/A, 1 filing Feb 11, 202269
SEC filer profile
How SkinHealth Systems Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARSkinHealth Systems Inc.1
- CIK0001818093
- Employer ID (EIN)85-19089625
- Filer statusAccelerated filer not an emerging growth company; not a smaller reporting company; not a shell company5
- Incorporated inDelaware5
- Fiscal year endsDecember 311
- Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address3600 E. Burnett Street, Long Beach, CA 908151
- Phone800-603-49961
- Shares outstanding130,140,763 as of Aug 3, 202612
- Public float$158.4M as of Jun 30, 20255
- AuditorDeloitte & Touche LLP, Los Angeles, California PCAOB ID 34; it also attests to the company’s internal control over financial reporting5
- On EDGAR sinceAug 12, 20201
- Filings438 in all: 4 (123), 8-K (94), 424B3 (32), 3 (28), SC 13G/A (24), 10-Q (18), DEFA14A (11), SC 13G (11)1
All 42 form types
SCHEDULE 13G/A (9), 8-K/A (8), UPLOAD (8), 10-K (6), CORRESP (6), DEF 14A (6), EFFECT (5), SCHEDULE 13G (5), ARS (4), SC 13D/A (4), 10-Q/A (3), 144 (3), PRER14A (3), 10-K/A (2), 25-NSE (2), NT 10-Q (2), POS AM (2), PRE 14A (2), S-1 (2), 4/A (1), 424B4 (1), 424B5 (1), 8-A12B (1), CERT (1), DEFM14A (1), DRS (1), NT 10-K (1), POS EX (1), PREM14A (1), S-1/A (1), S-3 (1), S-8 (1), SC 13D (1), SCHEDULE 13D/A (1)
- Latest filingsAnnual report (10-K) Mar 12, 2026
Quarterly report (10-Q) Aug 6, 2026
Proxy statement (DEF 14A) Aug 12, 2026
Latest 8-K (8-K) Oct 14, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Class A Common Stock, par value $0.0001 per share | SKIN | Nasdaq |
From the cover page of the 10-K filed Mar 12, 2026 (Section 12(b) of the Exchange Act).5
Risk factors and legal proceedings
The risks SkinHealth Systems Inc. names in Item 1A of its 10-K filed Mar 12, 2026: 72 risks under these headings, as written.5
- Risks related to the beauty health industry
- The beauty health industry is highly competitive, and if we are unable to compete effectively, our results will suffer.
- Our business is dependent on the commercial success and our ability to sell Delivery Systems. If we are unable to continue to successfully commercialize and sell our Delivery Systems, our results or operations and financial condition will be materially harmed.
- Our new product introductions may not be, and at times in the past have not been, as successful as we anticipate.
- Any damage to our reputation or brand may materially and adversely affect our business, financial condition and results of operations.
- Our success depends, in part, on the quality, efficacy and safety of our products.
- The illegal distribution and sale by third parties of counterfeit versions of our products or the unauthorized diversion by third parties of our products could have an adverse effect on our net sales and a negative impact on our reputation and business.
- Our reputation and brand may be negatively affected if our customers do not use our Delivery System as intended.
- Demand for our products may not increase as rapidly as we anticipate due to a variety of factors including a weakness in general economic conditions and resistance to non-traditional treatment methods.
- We may experience declines in average selling prices of our products which may decrease our net revenues.
- Risks related to our growth and profitability
- We may not be able to successfully implement our growth strategy.
The other 62 risks
- Our growth and profitability are dependent on a number of factors, and any historical growth may not be indicative of future growth.
- We may fail to realize all of the anticipated benefits of any entities that we acquire, such benefits may take longer to realize than expected or we may encounter significant difficulties integrating acquired businesses into our operations. If our acquisitions do not achieve their intended benefits, or do not achieve their intended benefits on our projected timelines, our business, financial condition, and results of operations could be materially and adversely affected.
- We may be unable to grow our business effectively or efficiently, which would harm our business, financial condition and results of operations.
- Acquisitions or investments could disrupt our business and harm our financial condition.
- Our operating results have fluctuated in the past and we expect our future quarterly and annual operating results to fluctuate for a variety of reasons, particularly as we focus on increasing provider and consumer demand for our products. Volatility in the financial markets could also have a material adverse effect on our business.
- We have a history of operating losses and may experience future losses.
- Risks related to our business operations
- A disruption in our operations could materially and adversely affect our business.
- Our success depends, in part, on our retention of key members of our senior management team, whose continued service is not guaranteed, and ability to attract and retain qualified personnel.
- We rely on a number of third-party suppliers, distributors and other vendors, and they may fail to produce products or to provide services that are consistent with our standards or applicable regulatory requirements, which could harm our brand reputation, cause consumer dissatisfaction or require us to find alternative suppliers of our products or services.
- We maintain single supply relationships for certain key components, and our business and operating results could be harmed if supply is restricted or ceases or the price of raw materials used in our manufacturing process increases.
- We rely on third-party delivery service providers.
- A disruption in the operations of our primary freight carrier or higher shipping costs could cause a decline in our net revenues or a reduction in our earnings.
- If we fail to manage our inventory effectively, our results of operations, financial condition and liquidity may be materially and adversely affected.
- In order to deepen our market penetration and raise awareness of our brand and products, we continue to spend on marketing activities, which may not ultimately prove successful or an effective use of our resources.
- We manufacture and assemble our Delivery Systems in California, and if this site were to become compromised or damaged, our ability to continue to manufacture and assemble our products would be negatively affected.
- We rely heavily on our sales professionals to market and sell our products worldwide. If we are unable to hire, effectively train, manage, improve the productivity of and retain our sales professionals, our business will be harmed, which would impair our future revenue and profitability.
- Our providers generally are not under any obligation to purchase product, and business challenges at one or more of these providers could adversely affect our results of operations.
- We may enter into collaborations, in-licensing arrangements, joint ventures, strategic alliances or partnerships with third parties that may not result in the development of commercially viable products or product improvements or the generation of significant future revenues.
- Risks related to our financial condition
- Our business could also be adversely affected by our inability to repay or refinance existing debt.
- If our cash from operations is insufficient to meet our current or future operating needs, expenditures and debt service obligations, our business, financial condition and results of operations may be materially and adversely affected.
- The terms of our Notes require us to meet certain operating and financial covenants and place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business.
- We maintain our cash at financial institutions, often in balances that exceed federally insured limits.
- Our ability to use any net operating loss carryforwards and certain other tax attributes may be limited.
- Changes in tax law, our tax rates or our exposure to additional income tax liabilities or assessments could materially and adversely affect our business, financial condition and results of operations.
- Our effective tax rate may vary significantly from period to period.
- Fluctuations in currency exchange rates may negatively affect our financial condition and results of operations.
- If our goodwill or long-lived assets become impaired, we may be required to record a significant charge to earnings.
- Volatility in the financial markets could have a material adverse effect on our business.
- Our sales and profitability may decline as a result of increasing costs and decreasing selling prices.
- Risks related to information technology and cybersecurity
- We are increasingly dependent on information technology, and if we are unable to protect against service interruptions, data corruption, cyber-based attacks or network security breaches, our operations could be disrupted.
- We must successfully maintain and upgrade our information technology systems, and our failure to do so could have a material adverse effect on our business, financial condition and results of operations.
- Privacy and data protection laws increase our compliance burden.
- We are subject to risks associated with product failure and/or technology flaws.
- If we fail to adopt new technologies or adapt our e-commerce websites and systems to changing consumer demands or emerging industry standards, our business may be materially and adversely affected.
- Failure to protect sensitive information of our consumers and information technology systems against security breaches could damage our reputation and brand and substantially harm our business, financial condition and results of operations.
- Payment methods used on our e-commerce websites subject us to third-party payment processing-related risks.
- We use AI in our business, and challenges with properly managing its use could result in harm to our brand, reputation, business or customers, and adversely affect our results of operations.
- Risks related to conducting business internationally
- International sales and operations comprise a significant portion of our business, which exposes us to foreign operational, political and other risks that may harm our business.
- Adverse economic conditions in the United States, Europe, China or any of the other countries in which we may conduct business could negatively affect our business, financial condition and results of operations.
- Legal, political, and economic uncertainty surrounding the exit of the United Kingdom from the European Union continue to be a source of instability and uncertainty.
- We conduct business in China, which exposes us to risks inherent in doing business in that country.
- Recent and potential additional tariffs imposed by the United States government on certain imports or a global trade war could increase the cost of our products, which could materially and adversely affect our business, financial condition and results of operations.
- Our business could be negatively impacted by changes in the United States political environment.
- Disruption due to any government shutdown and personnel or policy changes at regulatory agencies, including the FDA, may hinder our ability to operate our business as intended.
- Risks related to environmental, social, and governance issues
- Climate change and governmental actions to reduce such change may disrupt our operations and/or reduce consumer demand for our products.
- Increased scrutiny from investors and others regarding our environmental, social, governance, or sustainability, responsibilities could result in additional costs or risks and adversely impact our reputation, employee retention, and willingness of customers and suppliers to do business with us.
- Risks related to evolving laws and regulations and compliance with laws and regulations
- New laws, regulations, enforcement trends or changes in existing regulations governing the introduction, marketing and sale of our products to consumers could harm our business.
- New laws, regulations, enforcement trends, or changes in existing regulations could affect the ability of our esthetician providers in certain states to provide our treatments to consumers, any of which could have a material adverse effect on our business, financial condition, and results of operation.
- Uncertainty in regulatory frameworks and changes in applicable laws and regulations may affect our ability to commercialize products.
- Our employees, consultants, and other commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.
- Our facilities are subject to regulation under the FDCA and FDA implementing regulations governing the manufacture of our products. If we fail to comply with federal, state and foreign regulations, our manufacturing operations could be halted, and our business would suffer.
- The use, misuse or off-label use of our products may harm our reputation in the marketplace, result in injuries that lead to product liability suits or result in costly investigations, fines, or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these uses, any of which could be costly to our business.
- Government regulations and private party actions relating to the marketing and advertising of our products and services may restrict, inhibit, or delay our ability to sell our products and harm our business, financial condition and results of operations.
- Our products may cause or contribute to adverse medical events or other undesirable side effects that we are required to report to the FDA or foreign regulatory authorities, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial condition and results of operations. The discovery of serious safety issues with our products, or a recall of our products either voluntarily or at the direction of the FDA or another governmental authority, could have a negative impact on us.
- Changes in funding for, or disruptions caused by global health concerns impacting the FDA and other government agencies or notified bodies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products from being developed, authorized, or commercialized in a timely manner, which could negatively impact our business.
- If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our shares of Class A Common Stock.
- Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
- Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.
- Failure to comply with the U.S. FCPA, other applicable anti-corruption and anti-bribery laws, and applicable trade control laws could subject us to penalties and other adverse consequences.
- As compliance with healthcare regulations becomes more costly and difficult for us or our customers, we may be unable to grow our business.
- If we market products in a manner that violates healthcare laws, we may be subject to civil or criminal penalties.
- Government regulation of the Internet and e-commerce is evolving, and unfavorable changes or failure by us to comply with these regulations could substantially harm our business, financial condition and results of operations.
Legal proceedings
The Company is a party to various lawsuits, claims, and other legal proceedings that arise from time to time in the ordinary course of business, including but not limited to commercial disputes, product liability, and employment related matters. In addition, the Company may bring claims or initiate lawsuits from time to time against various third parties with respect to matters arising out of the ordinary course of the Company’s business, including but not limited to commercial and intellectual property related matters.
For the matters we disclose that do not include an estimate of the amount of loss or range of losses, such an estimate is not possible or is immaterial, and we may be unable to estimate the possible loss or range of losses that could potentially result from the application of non-monetary remedies. Until the final resolution of such matters, if any of our estimates and assumptions change or prove to have been incorrect, we may experience losses in excess of the amounts recorded, which could have a material effect on our business, consolidated financial position, results of operations, or cash flows.
Except as otherwise disclosed below, we believe that none of our pending lawsuits, claims, and other proceedings are expected to have a material adverse effect on the Company’s business, consolidated financial position, results of operations, or cash flows. However, management’s judgment may prove materially inaccurate, and such judgment is made subject to the known uncertainties of litigation.
Cartessa Aesthetics, LLC
The opening of Item 3, Legal Proceedings.5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16SEC EDGARIndra Pamamull, President
- 17SEC EDGARStephan Becker, President
- 18SEC EDGARLiyuan Woo, Chief financial officer
- 19
- 20SEC EDGARSheri Lewis, Chief operating officer
- 21
- 22
- 23SEC EDGARDaniel Copell Watson, Officer
- 24SEC EDGARE. Scott Beattie, Board member
- 25SEC EDGARKenneth Robert Tripp, Board member
- 26
- 27SEC EDGARPhilippe Schaison, Board member
- 28SEC EDGARStephen J. Fanning, Board member
- 29
- 30SEC EDGARDoug K. Schillinger, Board member
- 31SEC EDGARMichelle C. Kerrick, Board member
- 32SEC EDGARBrent Saunders, Board member
- 33SEC EDGARDesiree Gruber, Board member
- 34SEC EDGARJulius Few, Board member
- 35SEC EDGARMichael David Capellas, Board member
- 36
- 37
- 38SEC EDGARShareholder vote
- 39SEC EDGARExecutive or director change
- 40SEC EDGARExecutive or director change
- 41SEC EDGARResults of operations
- 42SEC EDGAROther events
- 43SEC EDGARShareholder vote
- 44SEC EDGARExecutive or director change
- 45SEC EDGARListing notice or transfer
- 46SEC EDGARResults of operations
- 47SEC EDGARExecutive or director change
- 48NasdaqNasdaq calendar
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69